{"id":"hl231-solution-for-inhalation","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108251","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a solution for inhalation, HL231 enables direct pulmonary delivery of its active pharmaceutical ingredient(s), potentially improving bioavailability and reducing systemic exposure compared to oral or parenteral routes. The specific mechanism depends on the active ingredient, which is not publicly disclosed in available sources. Inhalation formulations are typically used for respiratory conditions or to achieve rapid systemic absorption through the large surface area of the lungs.","oneSentence":"HL231 is an inhaled formulation designed to deliver therapeutic agents directly to the respiratory tract for local and/or systemic effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:44:45.197Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06619210","phase":"PHASE2","title":"A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-01-12","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":102},{"nctId":"NCT06643078","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2023-12-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":474}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HL231 Solution for Inhalation","genericName":"HL231 Solution for Inhalation","companyName":"Haisco Pharmaceutical Group Co., Ltd.","companyId":"haisco-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}